$RZLT

Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on developing therapies for refractory and debilitating hypoglycemia associated with hyperinsulinism. Its lead clinical asset, ersodetug, is an intravenously administered human monoclonal antibody designed to reduce insulin receptor activity. Rezolute is developing ersodetug for congenital hyperinsulinism and tumor-related hyperinsulinism, including hypoglycemia caused by insulinomas and other tumors. It also operates expanded access programs that provide ersodetug on a compassionate-use basis to patients with various forms of hyperinsulinism who cannot access a clinical trial. Rezolute is conducting Phase 3 studies of ersodetug for congenital HI and tumor HI. It is headquartered in Redwood City, California.

12
0
3

No SEC Form 4 filings for $RZLT in the last 30 days.

See all $RZLT insider activity →
Med

Wedbush raises Rezolute stock price target on tumor trial data

Wedbush raised its price target for Rezolute Inc. (RZLT) to $10 from $6, citing positive Phase 3 trial data. The new target suggests 179% upside from the current $3.58 share price. The firm increased its success probability for hyperinsulinism treatments and adjusted its revenue forecasts. Rezolute recently completed enrollment in a Phase 3 study and has strong liquidity, according to InvestingPro.

Rezolute, Inc. (RZLT): Entry into a Material Definitive Agreement

Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Transaction led by Frazier Life Sciences with participation from new and existing funds REDWOOD CITY, Calif., November 13, 2026 – Rezolute, Inc. (Na

Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism

Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism Primary efficacy endpoint achieved based on preliminary results from a November 5 th data evaluation Topline results for the completed study, along with additional study detail

RZLT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 15 news stories mentioning RZLT (Rezolute, Inc.). Coverage has skewed bullish: 12 bullish, 0 neutral, and 3 bearish.

Recent RZLT coverage spans financial news, corporate actions and earnings.

What's driving RZLT

AlphAI scores every news story that mentions RZLT with an AI model for sentiment and relevance, and aggregates insider trades from Rezolute, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RZLT

Score

Wedbush raises Rezolute stock price target on tumor trial data

Wedbush raised its price target for Rezolute Inc. (RZLT) to $10 from $6, citing positive Phase 3 trial data. The new target suggests 179% upside from the current $3.58 share price. The firm increased its success probability for hyperinsulinism treatments and adjusted its revenue forecasts. Rezolute recently completed enrollment in a Phase 3 study and has strong liquidity, according to InvestingPro.

$RZLTHighOffering· $100M · priced

Rezolute, Inc. (RZLT): Entry into a Material Definitive Agreement

Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Transaction led by Frazier Life Sciences with participation from new and existing funds REDWOOD CITY, Calif., November 13, 2026 – Rezolute, Inc. (Na

$RZLTHighAI 9/10Clinical / regulatory· topline data

Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism

Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism Primary efficacy endpoint achieved based on preliminary results from a November 5 th data evaluation Topline results for the completed study, along with additional study detail

$RZLTMedEarnings

Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update

Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update REDWOOD CITY, Calif., November 5, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refracto

$RZLTHighAI 8/10

Rezolute stock holds Buy rating at H.C. Wainwright on trial progress

H.C. Wainwright reiterated a Buy rating and $10.00 price target on Rezolute (RZLT) after the company completed enrollment in its Phase 3 upLIFT study. The stock is down 8.8% over the past week but up 79% year-to-date. Analysts have a strong buy consensus with price targets ranging from $6 to $15. Rezolute expects topline results from the study in mid-December 2026. The company reported positive interim data and no drug-related safety findings.

$RZLTMedAI 8/10

Citizens reiterates Market Outperform on Rezolute stock on trial data

Citizens reiterated a Market Outperform rating and $15.00 price target for Rezolute (RZLT) after the company completed enrollment in its Phase 3 trial for ersodetug. The stock is currently trading at $4.23, with analyst price targets ranging from $6 to $15. Rezolute expects top-line results in mid-December, earlier than previously anticipated. Analysts cite positive interim results and FDA feedback as reasons for optimism.

$RZLTMedAI 8/10Clinical / regulatory· trial start

Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Topline results expected mid-December 2026 REDWOOD CITY, Calif., October 14, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare

$RZLTLowAI 8/10

Rezolute completes enrollment in phase 3 tumor study

Rezolute Inc. (RZLT) completed enrollment in its Phase 3 study of ersodetug for tumor hyperinsulinism, with 16 participants. Topline results are expected in mid-December 2026. The study's primary endpoint measures a 50% reduction in glucose infusion rate. Seven of the first eight participants met the responder criterion, and the treatment has been well-tolerated. Rezolute plans to continue its expanded access program.

Related tickers